C12N15/03

BIOCATALYST COMPRISING PHOTOAUTOTROPHIC ORGANISMS PRODUCING RECOMBINANT ENZYME FOR DEGRADATION OF HARMFUL ALGAL BLOOM TOXINS
20190263871 · 2019-08-29 ·

The invention comprises a photoautotrophic organism, generally having simpler nutritional requirements than heterotrophic organisms, utilized as a chassis for the heterologous expression and function of enzymes, or derivatives of said enzymes, that show activity toward the degradation/detoxification of toxins known to be associated with and specific to harmful algal blooms. As an example, a cyanobacterial strain (Synechocystis sp. PCC 6803) modified to express Sphingomonas sp. USTB-05 MlrA enzyme functionality, showing the capability of degrading microcystins (results shown here) and nodularins, is presented. Under modelled natural conditions, results indicate that heterologous enzymatic activity against microcystin-LR is more stable over time when utilizing a photoautotrophic chassis in comparison to use of a heterotrophic bacterial strain. In addition, both the viability and cell density of the photoautotrophic host is maintained for a significantly longer period of time, compared to a heterotrophic host.

BACTERIAL STRAIN PRODUCING 2,3-BUTANEDIOL AND OTHER METABOLITES

The present invention provides a modified strain of the bacterium Lactococcus lactis obtainable by a method that comprises a step of fusion of two protoplasts from two Lactococcus lactis parental strains which, compared to the wild type strain of Lactococcus lactis from which they derive, show: (a) an increased ability to produce acetoin and/or 2,3-butanediol (2,3-BDO), and (b) a decreased ability to produce lactic acid, when cultured under aerobic conditions, and wherein the modified strain of Lactococcus lactis has an increased ability to produce 2,3-BDO of at least 20 times the amount produced by the wild type strain, an increased ability to produce acetoin of at least 20 times the amount produced by the wild type strain and a decreased ability to produce lactic acid of at least 10 times the amount produced by the wild type strain, when cultured under aerobic conditions. Also provided are methods to produce acetoin and 2,3-BDO.

Prokaryotic collagen therapeutics for postoperative adhesions

The present invention includes a synthetic collagen that facilitates adhesion prevention and methods of use thereof. The present invention includes a prokaryotic collagen that facilitates adhesion prevention and treatment and methods of use thereof. The prokaryotic collagen includes an isolated and purified triple helical backbone protein that facilitates adhesion prevention: one or more alteration in a triple helical backbone protein sequence, and one or more binding motifs, wherein the isolated and purified triple helical backbone protein facilitates adhesion prevention.

Prokaryotic collagen therapeutics for postoperative adhesions

The present invention includes a synthetic collagen that facilitates adhesion prevention and methods of use thereof. The present invention includes a prokaryotic collagen that facilitates adhesion prevention and treatment and methods of use thereof. The prokaryotic collagen includes an isolated and purified triple helical backbone protein that facilitates adhesion prevention: one or more alteration in a triple helical backbone protein sequence, and one or more binding motifs, wherein the isolated and purified triple helical backbone protein facilitates adhesion prevention.

Host cells with artificial endosymbionts

The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.

Host cells with artificial endosymbionts

The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.

Isoform of the TGF-beta receptor II

An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain; wherein the isoform is a TGF-1 agonist. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2.

Method for constructing trehalose multi-enzyme complex in vitro mediated by artificial scaffold protein

The present disclosure relates to a method for constructing a trehalose polyenzyme complex in vitro by mediation of an artificial scaffold protein, which mainly comprises the following steps: constructing a recombinant bacterium WB800n-ScafCCR for self-assembled scaffold protein module; constructing a recombinant bacterium WB800n-P43-phoD -treY-Ccdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-treZ-Ctdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-cgt-Rfdoc for self-assembled catalytic module; secretorily expressing the recombinant bacteria and self-assembling in vitro to obtain a recombinant trehalose multi-enzyme complex. The trehalose multi-enzyme complex constructed by the method of the present disclosure has a higher catalytic efficiency in preparing trehalose than that of mixed free enzymes, and the method can be used for production of high quality trehalose after immobilization with cellulose microspheres.

Method for constructing trehalose multi-enzyme complex in vitro mediated by artificial scaffold protein

The present disclosure relates to a method for constructing a trehalose polyenzyme complex in vitro by mediation of an artificial scaffold protein, which mainly comprises the following steps: constructing a recombinant bacterium WB800n-ScafCCR for self-assembled scaffold protein module; constructing a recombinant bacterium WB800n-P43-phoD -treY-Ccdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-treZ-Ctdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-cgt-Rfdoc for self-assembled catalytic module; secretorily expressing the recombinant bacteria and self-assembling in vitro to obtain a recombinant trehalose multi-enzyme complex. The trehalose multi-enzyme complex constructed by the method of the present disclosure has a higher catalytic efficiency in preparing trehalose than that of mixed free enzymes, and the method can be used for production of high quality trehalose after immobilization with cellulose microspheres.

IMPROVED PROPIONIBACTERIUM STRAINS FOR THE PRODUCTION OF PROPIONIC ACID

Disclosed herein are new strains of Propionibacterium and methods for the biosynthetic production of propionic acid.